FAM207A

Across TCGA pan-cancer cohorts, FAM207A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM207A data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FAM207A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM207A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, HNSC, and UCEC are the cancer types where FAM207A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.121	0.627	<.001	30	view →
HNSC	OS	Median	All	0.196	0.751	.004	27	view →
UCEC	DFS	Median	All	1.000	0.627	.017	20	view →
CESC	DFS	Median	All	0.209	0.743	.002	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM207A–BLCA (DFS)

Open the BLCA breakdown →